Rosemont Pharmaceuticals was established in Leeds in 1967 by two pharmacists who were concerned about the lack of liquid medicines available for their patients who couldn’t swallow tablets or capsules.
The company has continued to bring liquid medicines to the market and campaigns on behalf of vulnerable patients with swallowing difficulties.
In 1974, the company's first liquid medicine was granted a license. It has continued to invest in research and development, developing more medicines in a liquid format, to support both healthcare professionals and their patients.
In 2013 the business was sold to Perrigo in the US. In 2020 Perrigo decided that Rosemont was non-core and sold the business to Inflexion.
Howard Taylor, the CEO of Rosemont Pharmaceuticals, said: "We have been in Leeds for more than 50 years and have 200 employees across our sites in Holbeck and Geldard Lane, which includes R&D (research and development) operations, manufacturing and quality control.
"We plan to continue investing in our site in Holbeck and are looking to build a new building on the site. Within five years we could aim to have 300 staff in Leeds."
"Leeds is an up and coming city with plenty of vibrancy and investment and five universities.
"We hope to draw talent to Leeds from the rest of the country. We are looking to attract people internationally as well.
"It's been a real joy to work with a private equity house like Inflexion."
"We are looking at acquiring new businesses and bolting them on to our base in Leeds."
Rosemont Pharmaceuticals has a portfolio of more than 130 oral liquid medicines. It includes 70 licensed products which are sold into the UK as well as the US, Europe and the Middle East.